scholarly journals Tumor Markers Reflect Tumor Burden of Pseudomyxoma Peritonei

2021 ◽  
Author(s):  
Mingjian Bai ◽  
Shaojun Pang ◽  
Yiyan Lu ◽  
Hongjiang Wei ◽  
Jing Feng ◽  
...  
Keyword(s):  
Tumor Markers ◽  
Pseudomyxoma Peritonei ◽  
Peritoneal Cancer Index ◽  
Tumor Burden ◽  
Ca 125 ◽  
P Value ◽  
Peritoneal Cancer ◽  
Serum Tumor Markers ◽  
Ca 242 ◽  
Preoperative Serum

Abstract Background: Accurate assessment of preoperative tumor burden contribute to formulate a scientific surgical plan and improve the prognosis of patients with pseudomyxoma peritonei (PMP). Present study aimed to assess whether preoperative serum tumor markers could reflect tumor burden. Methods: A total of 198 PMP patients were included, the peritoneal cancer index (PCI) was employed to reflect tumor burden for PMP patients. All participants were divided into low (PCI ≤ 19) and high (PCI ≥ 20) tumor burden subgroups according to PCI. All serum tumor markers (carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), CA 19-9, CA 724, and CA 242) were compared between the two subgroups. The correlation between tumor markers and PCI will be calculated and compared with each other. Two-sided P value less than 0.05 is considered statistically significant.Results: The level of CEA (ng/ml), CA125 (U/ml), CA 19-9 (U/ml), CA 724 (U/ml), and CA 242 (kU/L) between low and high tumor burden subgroup were [3.35 (1.64, 16.31) vs. 23.12 (8.80, 67.62), Z = -5.381, p<0.001], [19.10 (7.61, 56.95) vs. 72.75 (40.41, 130.55), Z = -5.978, p < 0.001], [6.17 (3.26, 16.22) vs. 45.50 (13.95, 123.61), Z = -5.413, p < 0.001], [7.89 (1.57, 45.10) vs. 84.61 (33.87, 236.93), Z = -5.898, p < 0.001], and [13.32 (3.39, 96.50) vs. 150.00 (102.13, 308.88), Z = -5.166, p < 0.001], respectively. The Spearman correlation between tumor markers and PCI were 0.415 for CEA (p < 0.001), 0.372 for CA 125 (p < 0.001), 0.466 for CA 19-9 (p < 0.001), 0.379 for CA 724 (p < 0.001), and 0.317 for CA 242 (p < 0.001), respectively. Conclusions: Preoperative serum tumor markers could moderately reflect tumor burden for PMP, which may contribute to develop a better surgical plan before operation.

Circulating tumor DNA as a prognostic factor in peritoneal carcinomatosis after hyperthermic intraperitoneal chemotherapy.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16280-e16280
Author(s):  
Zongyuan Li ◽  
Xiaolin Pu ◽  
Hua Jiang
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Tumor Markers ◽  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Peritoneal Cancer Index ◽  
Circulating Tumor Dna ◽  
Plasma Samples ◽  
Peritoneal Cancer ◽  
Time Points ◽  
Tumor Dna

e16280 Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is the main treatment for peritoneal carcinomatosis (PC).However, It is still a major problem to predict the efficacy of HIPEC. Some studies have shown that peritoneal cancer index (PCI) can be used to predict the efficacy of HIPEC, but the invasiveness and inaccuracy are shortcomings. Therefore, we need a minimally invasive and accurate prediction biomarker. Many studies have confirmed that circulating tumor DNA (ctDNA) can accurately predict the efficacy and prognosis of various solid tumors. This study aimed to evaluate the predictive value of ctDNA from ascites and plasma for HIPEC. Methods: Eligible PC patients should be defintive diagnosed by pathology or cytology. Each patient was treated with HIPEC for 4 times, with an interval of 3 days each time. Plasma and ascites samples were collected before HIPEC and after the last HIPEC. All samples were detected by next generation sequencing (NGS). The molecular tumor burden index (mTBI) and main clone variant allele fraction (VAF) changes were used as the prediction indexes of efficacy. In addition, The changes of common tumor markers such as CEA during the same period were used as controls. Results: A total of 19 patients with PC were enrolled from November 2018 to January 2020. Firstly, the mTBI changes of 14 patients whom had plasma samples at two time points (baseline and postHIPEC)were analyzed. Among them, 3 patients had no gene mutation were detected in two time points. There were significant differences in mTBI before and after HIPEC in the remaining 11 patients (Wilcoxon， p = 0.026). the median Ascites progression free survival (PFS) was 3.35 months (95% CI: 2.34 – 5.13 months), and the median overall survival (OS) was 5.93 months (95% CI: 4.93 – 11.17 months). The mTBI decline was significantly positively correlated with ascites PFS (Spearman r = 0.673, p = 0.023) and moderately positively correlated with OS (Spearman r = 0.510, p = 0.109). The highest VAF in plasma samples was defined as the main clone mutation. The main clone VAF decline was moderately positively correlated with ascites PFS (Spearman r = 0.588, p = 0.057) and slightly positively correlated with OS (Spearman r = 0.386, p = 0.241). As the controls, We found that the common tumor markers decline was no correlated with ascites PFS(Spearman r = 0.091, p = 0.790) and OS (Spearman r = 0.287, p = 0.396). We further analyzed the correlation of VAF between ascites and plasma co-mutation genes in 12 patients. The VAF of co-mutated genes in plasma and ascites was positively correlated (Spearman r = 0.794, p = 0.001). Conclusions: Plasma ctDNA can be used as a biomarker for predicting the efficacy of HIPEC for peritoneal carcinomatosis, and its accuracy is significantly higher than comon tumor markers. However, a larger sample size study are needed to validate our results.

scholarly journals The association of five preoperative serum tumor markers and pathological features in patients with breast cancer

2019 ◽  
Vol 33 (5) ◽  
Author(s):  
Mingjian Lian ◽  
Cuixia Zhang ◽  
Dongdong Zhang ◽  
Ping Chen ◽  
Huijing Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Markers ◽  
Pathological Features ◽  
Serum Tumor Markers ◽  
Preoperative Serum

Elevated CA 19-9 Levels in Mature Cystic Teratoma of the Ovary

2009 ◽  
Vol 24 (1) ◽  
pp. 52-56 ◽  
Author(s):  
Min Sun Kyung ◽  
Joong Sub Choi ◽  
Seung Hwa Hong ◽  
Hak Soon Kim
Keyword(s):  
Tumor Markers ◽  
Elevated Serum ◽  
Cystic Teratoma ◽  
Ovarian Torsion ◽  
Mature Cystic Teratoma ◽  
Ca 125 ◽  
Clinical Value ◽  
Blood Samples ◽  
Serum Tumor Markers

The purpose of this study was to evaluate the clinical value of serum tumor markers in patients with ovarian mature cystic teratoma (MCT). We retrospectively evaluated 163 women who underwent surgery for MCT of the ovary between March 2003 and August 2007 and who provided preoperative blood samples for the measurement of CA 19-9 and CA 125. The rates of elevated serum CA 19-9 and CA 125 levels were 31.9% (52/163) and 13.5% (22/163), respectively. The rate of ovarian torsion was 12.9% (21/163). There were significant differences between the elevated CA 19-9 group and the normal CA 19-9 group in the diameters of the tumors and the rates of ovarian torsion. Elevated serum CA 19-9 levels correlated with larger tumor diameters and higher torsion rates. CA 19-9 may be a useful tool for the diagnosis of ovarian MCT. Elevated CA 19-9 levels appear to correlate with larger tumor diameters and higher rates of ovarian torsion.

A phase II randomized, double-blind, placebo-controlled trial of clinical activity and safety of Å6 in patients with asymptomatic CA 125 progression of epithelial ovarian, fallopian tube, or primary peritoneal cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 16014-16014 ◽  
Author(s):  
S. Ghamande ◽  
M. Silverman ◽  
M. Gold ◽  
W. Huh ◽  
K. Behbakht ◽  
...  
Keyword(s):  
Disease Progression ◽  
Fallopian Tube ◽  
Small Sample ◽  
Ca 125 ◽  
Clinical Activity ◽  
P Value ◽  
High Dose ◽  
Fisher Exact Test ◽  
Primary Peritoneal Cancer ◽  
Peritoneal Cancer

16014 Background: Patients (pts) with epithelial ovarian cancer (EOC) often relapse and rising CA 125 levels predate clinical or radiological appearance of tumor. High tumor and serum levels of urokinase plasminogen activator (uPA) in EOC correlate to adverse outcomes. Å6 is a novel peptide derived from human uPA that down-regulates the uPA system and has anti-angiogenic and anti-metastatic activity in animals. Methods: Pts with EOC, fallopian tube, or primary peritoneal cancer in clinical remission after first line chemotherapy had to have 2 consecutive rises of CA 125 levels above normal with no disease on physical examination or imaging studies. Pts were randomized to receive daily subcutaneous injections of placebo, 150 mg Å6, or 300 mg Å6 until disease progression. The primary objectives were to assess safety and clinical activity of Å6 by the effect on the onset of disease progression. Results: 48 pts were planned for the study. The trial ended early with 24 patients {12 pts (50%) placebo, 8 pts (33%) low dose Å6, 4 pts (17%) high dose Å6} randomized, treated and followed for up to 9 months. Despite early study termination and small sample size, A6 therapy was associated with a statistically significant progression free survival (PFS) (log rank p value=0.01) with a median PFS of 100 days (95% CI 64,168) compared to 49 days (95% CI 29,67) in pts who received the placebo. The treatments were well tolerated with one serious adverse event (transient nausea and dyspnea ) possibly related to study drug. Treatment was not associated with CA 125 response (Fisher exact test p value= 0.44). Conclusions: Å6 therapy increases PFS of patients with EOC and asymptomatic progression of CA 125. This therapy is novel, safe, feasible and deserves further investigation [Table: see text]

scholarly journals The Prognostic Value of Preoperative Serum Tumor Markers in Non-Small Cell Lung Cancer Varies With Radiological Features and Histological Types

2021 ◽  
Vol 11 ◽  
Author(s):  
Haiqing Chen ◽  
Fangqiu Fu ◽  
Yue Zhao ◽  
Haoxuan Wu ◽  
Hong Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Tumor Markers ◽  
Cell Lung Cancer ◽  
Carbohydrate Antigen ◽  
Small Cell ◽  
Small Cell Lung ◽  
Serum Tumor Markers ◽  
Preoperative Serum

ObjectivesTo assess the association between common-used serum tumor markers and recurrence of lung adenocarcinoma and squamous cell carcinoma separately and determine the prognostic value of serum tumor markers in lung adenocarcinoma featured as ground glass opacities.MethodsA total of 2,654 non-small cell lung cancer patients undergoing surgical resection between January 2008 and September 2014 were analyzed. The serum levels of carcinoma embryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) and carbohydrate antigen 199 (CA199) were tested preoperatively. Survival analyses were performed with COX proportional hazard regression.ResultsAmong patients with lung adenocarcinoma, elevated preoperative serum CEA(HR=1.246, 95%CI:1.043-1.488, P=0.015), CYFRA21-1(HR=1.209, 95%CI:1.015-1.441, P=0.034) and CA125(HR=1.361, 95%CI:1.053-1.757, P=0.018) were significantly associated with poorer recurrence free survival (RFS). Elevated preoperative serum CA199 predicted worse RFS in patients diagnosed with lung squamous cell carcinoma (HR=1.833, 95%CI: 1.216-2.762, P=0.004). Preoperative serum CYFRA21-1(HR=1.256, 95%CI:1.044-1.512, P=0.016) and CA125(HR=1.373, 95%CI: 1.050-1.795, P=0.020) were independent prognostic factors for patients with adenocarcinoma presenting as solid nodules while serum CEA (HR=2.160,95%CI:1.311-3.558, P=0.003) and CA125(HR=2.475,95%CI:1.163-5.266, P=0.019) were independent prognostic factors for patients with adenocarcinoma featured as ground glass opacities.ConclusionsThe prognostic significances of preoperative serum tumor markers in non-small cell lung cancer were associated with radiological features and histological types.

scholarly journals Construction of a Lymph Node Metastasis Nomogram Prediction Model Based on Dual-Energy CT Radiomics of Gastric Cancer Lesions

2021 ◽  
Author(s):  
Hong-li CUN ◽  
Qian-ting DUAN ◽  
Ying-ying DING ◽  
Da-fu Zhang ◽  
Ling YANG ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Markers ◽  
Iodine Concentration ◽  
Dual Energy ◽  
Dual Energy Ct ◽  
Test Set ◽  
Serum Tumor Markers ◽  
Node Metastasis ◽  
Preoperative Serum ◽  
Auc Value

Abstract Background This study aimed to explore the value of gastric cancer (GC) tumor markers and dual-energy CT（DECT） scans of arterial and venous GC lesions with quantitative iodine concentration (IC) and radiomics, to predict lymph node metastasis (LNM) in patients with GC. Methods This prospective study comprised of 177 patients that underwent dual-energy CT scans before surgery, and were subsequently diagnosed with GC by postoperative pathology. Serum tumor markers and arterial phases (AP) and venous phases (VP) of GC lesion iodine concentration (IC) and normalized iodine concentration (nIC) were analyzed. Patients were divided into either the LNM group or non-LNM group according to pathological results. The Wilcoxon rank-sum test was used to compare the serum tumor markers, IC, and nIC of the 2 groups, and a ROC curve was drawn to evaluate their effectiveness in predicting LNM in patients with GC. After using the Siemens syngo.via Frontier Radiomics software to extract radiomics features , all patients were randomly divided into a train set and a test set with a 7:3 ratio to predict GC LNM. Results Among the 177 patients with GC, 83 were diagnosed with LNM, while 94 did not have LNM. The preoperative serum tumor markers CA125, CA199, and CEA were statistically significant for predicting the presence of LNM (P<0.05). In the transfer group, AP and VP IC were 2.63 mg/ml (2.3, 3.00) and 3.60 mg/ml (3.23, 4.03) respectively, with corresponding areas under the curve (AUC) of 0.83 and 0.91. The nIC was 0.18 mg/ml (0.15, 0.21) and 0.78 mg/ml (0.65, 0.86); the AUC curve was 0.79 and 0.87. Both the IC and nIC were higher in the patients with LNM than those without LNM (P<0.05). Establishing a random forest (RF) model based on the radiomics extracted from the GC lesions had a high diagnostic value in predicting whether the lymph nodes in patients with GC were metastatic. The RF model AUC value was 0.959 for the train set and 0.977 for the test set. The AUC value of the nomogram predicting LNM was 0.996 for the train set and 0.976 for the test set. Conclusion Models based on preoperative serum tumor markers (CA125, CA199, and CEA) in patients with GC, quantitative dual-energy CT parameter values of the lesions (AP and VP IC, nIC), and radiomics have a higher diagnosis of LNM. The value of nomogram in combination with multi-parameter analysis is higher diagnosis of LNM, which can provide a reliable basis for preoperative evaluation of LNM.

scholarly journals Significance of serum tumor markers monitoring in carcinomas of unknown primary site

2010 ◽  
Vol 67 (9) ◽  
pp. 723-731 ◽  
Author(s):  
Ivica Pejcic ◽  
Svetislav Vrbic ◽  
Sladjana Filipovic ◽  
Mirjana Scekic ◽  
Ivan Petkovic ◽  
...  
Keyword(s):  
Survival Time ◽  
Tumor Markers ◽  
Primary Site ◽  
Ca 125 ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Average Survival Time ◽  
Primary Tumors ◽  
Serum Tumor Markers ◽  
Average Survival

Background/Aim. Unknown primary tumors represent a heterogeneous group of malignancies that are indicative of ominous prognosis. Cancer of unknown primary site (CUP) is defined as the lack of any detectable primary site after full evaluation, and accounts for approximately 3-5% of all newly diagnosed patients with malignancies. The aim of this report was to present the prognostic and predictive value of 8 serum tumor markers in this group of patients. Methods. The study involved 63 patients. On histological examination, all the patients were presented with metastatic tumors whose primary site (origin) could not be detected with noninvasive diagnostic techniques. Following the routine light microscopy, all histological findings were classified into one of the following three groups: plano-cellular carcinoma - 8 patients; adenocarcinoma - 33 patients; unclassifiable (undifferentiated) carcinoma - 22 patients. In all the cases we evaluated 8 serum tumor markers: alpha-fetoproteins (AFP), chronic gonadotrophin beta submit, human (beta-HCG), neuron specific enolase (NSE), marker of malignant ovarian tumors (CA 125), prostate-specific antigene (PSA), marker of malignant brest tumor (CA 15-3), marker of malignant pancreas tumor and gastrointestinal tumor (Ca 19-9), carcinoembryonic antigen (CEA) at the time of diagnosis. The patients on chemotherapy had the markers determined after the third and sixth chemocycle, i.e. at the time of illness progression observation, if present. The patients responding to chemotherapy with complete response (CR), partial response (PR) or stable disease (SD) had the markers determined after three-month periods until the time of relapse or progression. Chemotherapy was applied in 32 patients (20 females and 12 males), aged 29-70 years, who met the inclusion criteria. The following chemotherapy regimen was used: doxorubicin 50mg/m2 (day 1), cisplatin 60mg/m2 (day 1), and etoposide 120 mg/m2 (days 1-3). The period between two chemotherapy cycles was three weeks, and maximum five weeks in the case of prolonged hematological toxicity. Results. Most commonly elevated were NSE values (82.54%), while AFP values were least commonly elevated (11.11%). Average survival time was 17.89 months (95%CI 12.96; 22.83). The probability of 24 months' survival was 0.228. The group of 32 patients treated with chemotherapy had 12 (37.5%) fatal outcomes in the observed period (72 months). Average survival time was 26.6 months (95% CI 19.5; 33.7). Average tumor marker values before and after the chemotherapy were significantly lower for NSE and CA 125. Survival was significantly better in cases of NSE and CA 125 decrease of more than 20%. Conclusion. Increased values of serum tumor markers are very often in CUP. The tumors show nonspecific overexpression of tumor markers. The NSE and CA 125 levels show good correlation with response to the given chemotherapy. However, a routine evaluation of commonly used serum tumor markers has not been proven of any prognostic and predictive assistance.

scholarly journals The difference in prognosis of stage II and III colorectal cancer based on preoperative serum tumor markers

2019 ◽  
Vol 10 (16) ◽  
pp. 3757-3766 ◽  
Author(s):  
Weiqiang You ◽  
Nengquan Sheng ◽  
Li Yan ◽  
Hongqi Chen ◽  
Jianfeng Gong ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Tumor Markers ◽  
Stage Ii ◽  
Serum Tumor Markers ◽  
Preoperative Serum ◽  
The Difference
Sign in / Sign up

Export Citation Format

Share Document